Lilly rolls out employer-facing access platform for GLP-1 obesity meds
Eli Lilly launches Employer Connect, a direct-to-employer program for GLP-1 obesity drugs that partners with 15+ administrators to let employers tailor coverage, including a discounted Zepbound KwikPen price of $449, with out-of-pocket costs varying by plan and options spanning telehealth, pharmacy-focused, and cardiometabolic care platforms.